Sutro Biopharma (STRO) — Cash Flow Reinvestment Rate

Latest as of June 2024: 8.58x

Sutro Biopharma (STRO) has a Cash Flow Reinvestment Rate of 8.58x as of June 2024, reinvesting $81.13 Million (capex $756.00K plus investments $-80.38 Million) from operating cash flow of $9.46 Million. Check earnings quality score of Sutro Biopharma to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

8.58x
(Capex + Investments) / Operating CF

Total Reinvested

$81.13 Million
Capex + Investments

Operating Cash Flow

$9.46 Million
USD

Capital Expenditures

$756.00K
USD

Sutro Biopharma Cash Flow Reinvestment Rate (2018–2022)

Historical reinvestment intensity for Sutro Biopharma across 2 annual periods. Explore STRO long-term investments to assets to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Sutro Biopharma (2018–2022)

Year-by-year capital reinvestment analysis for Sutro Biopharma. For live market cap and broader valuation context, see STRO stock market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2022 12.08x $42.88 Million $3.55 Million $7.86 Million ▲ +90.9%
2018 6.33x $80.27 Million $12.68 Million $1.56 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow